Christopher Slapak

Christopher Slapak

Plus aucun poste en cours

65 ans
Health Technology
Consumer Services
Health Services

Profil

Christopher Slapak worked as Vice President-Early Phase Development Oncology at Eli Lilly & Co. from 1996 to 2017.
He also worked as an Assistant Professor at Dana-Farber Cancer Institute, Inc. and as an Associate Professor-Clinical at The Indiana University School of Medicine.
In 2018, he became the Chief Medical Officer at Prelude Therapeutics, Inc. and in 2020, he became the Chief Medical Officer at Vor Biopharma, Inc. Dr. Slapak received his undergraduate degree from The Ohio State University and his doctorate degree from Pritzker School of Medicine.

Anciens postes connus de Christopher Slapak

SociétésPosteFin
VOR BIOPHARMA INC. Directeur Technique/Scientifique/R&D 06/05/2022
PRELUDE THERAPEUTICS INCORPORATED Directeur Technique/Scientifique/R&D 01/06/2019
ELI LILLY AND COMPANY Corporate Officer/Principal 01/12/2017
The Indiana University School of Medicine Corporate Officer/Principal -
Corporate Officer/Principal -
Voir l'expérience en détail de Christopher Slapak

Formation de Christopher Slapak

Pritzker School of Medicine Doctorate Degree
The Ohio State University Undergraduate Degree

Expériences
Fonctions occupées

Actives

Inactives

Sociétés cotées

Entreprise privées

Voir l'expérience en détail de Christopher Slapak

Relations

100 +

Relations au 1er degré

7

Entreprises liées au 1er degré

Homme

Femme

Administrateurs

Exécutifs

Voir le réseau personnel

Sociétés liées

Sociétés cotées3
VOR BIOPHARMA INC.

Health Technology

PRELUDE THERAPEUTICS INCORPORATED

Health Technology

ELI LILLY AND COMPANY

Health Technology

Entreprise privées1

Health Services

Voir les connexions sociétés
  1. Bourse
  2. Insiders
  3. Christopher Slapak